Cognex Q3 2026: Waiting for AI Proof

What happened

Cognex reported Q3 2026 results on November 5, with management likely discussing progress in AI-powered vision products. While the exact figures were not provided in the data, the call would have covered revenue growth, margin performance, and updates on OneVision and In-Sight adoption. The master report from May had set clear checkpoints for Q3, including evidence of repeat AI deployments and revenue contribution. Management's commentary on the call would determine whether the commercialization case has moved from narrative to operating proof. Without explicit confirmation of material AI revenue or broad-based multi-site rollouts, the investment thesis remains dependent on future quarters.

Implication

Investors should focus on whether management quantified AI-derived revenue or named specific multi-site deployments. If the call lacked such specifics, the stock remains a show-me story trading at 73x earnings, and patience is warranted. A break above $72 would signal the market is pricing in success, while a pullback toward $52 would offer a better entry. The next catalysts are the Q4 results and early 2027 commentary on OneVision attach rates.

Thesis delta

The thesis has not materially shifted until Q3 results show either explicit AI revenue contribution or evidence of stalled adoption. The WAIT rating remains appropriate as the stock already prices in a successful AI-led growth trajectory. A meaningful upgrade would require management to guide to accelerating AI-driven revenue and margin expansion.